China’s Life Sciences Regulatory Crackdown: September 10 Update

by Reed Smith
Contact

The regulatory enforcement environment in China remains tense, as both the Chinese government and media bring new actions and allegations against life sciences manufacturers in both the pharmaceutical and device sectors. We are seeing:

  • Increased attention to medical device sector
  • Enforcement actions spreading to smaller cities
  • Continued pressure on pharmaceutical sector
  • Reports of misconduct by local manufacturers
  • Questionable vendors named

Reed Smith continues to monitor the life sciences regulatory and media environment in China and has prepared the following summary regarding recent developments.

Medical Devices

New Media Reports

On, September 6, The 21st Century Business Herald, a Guangdong newspaper, published a lengthy feature entitled “The Underlying Causes of Excessive Medical Care,” including an article entitled “The Artificially High Cost of Medical Devices: For Every Stent Implanted, Doctors Receive At Least 2000 RMB in Kickbacks.” The 21st Century Business Herald previously published anonymous allegations naming three multinational pharmaceutical companies as being engaged in the bribery of doctors in China.

The article alleges that medical devices are marked up 200 percent to 300 percent over their import price, with some being marked up as much as 1000+ percent. With respect to stents, the article claims that Chinese doctors frequently implant stents in patients who do not need them, or implant too many stents in patients in order to obtain kickbacks from manufacturers. The article claims that the import price of foreign manufacturers’ stents is 6000 RMB, which increases to 20,000 RMB when sold to the consumer, of which the doctor receives 10 percent to 15 percent as a kickback.

The article also makes allegations regarding diagnostic tests and capital equipment. The article claims that a U.S. manufacturer’s color blood flow imaging system was sold to a hospital for 980,000 RMB, of which up to 100,000 RMB was a kickback to the hospital director. The article alleges that although the Chinese government has implemented centralized purchasing for some medical supplies and devices, doctors are unwilling to use such products because they cannot receive kickbacks through the centralized purchasing process.

The article also alleges that hospitals systematically arrange CT scans and blood tests for patients that are not necessary, and that sometimes negatively impact patients’ health, in order to generate more fees.

Enforcement Actions

The Ministry of Commerce (MofCom) and National Development and Reform Commission (NDRC) may be gathering information on the medical device industry, potentially in preparation for an antitrust or anti-corruption investigation. On August 21, Reuters reported that the Chinese Association of Medical Device Industry (CAMDI)1 is conducting a survey of member companies that asked for an unusual amount of detail regarding their pricing and business practices. One device manufacturer expressed concern that the survey was potentially being used to gather information for an investigation by authorities. CAMDI subsequently issued a statement acknowledging that it had received a questionnaire from MofCom and forwarded the questionnaire to some members, but denying that it had been formally entrusted by MofCom’s antitrust division to do so. CAMDI also stated that the questionnaire focused on barriers to market entry, rather than on pricing and sales techniques. The NDRC and MofCom further issued statements denying that they were engaged in investigations specifically targeting the medical device industry or that they had specifically entrusted CAMDI to conduct such investigations. The NDRC is currently conducting investigations of the automotive, jewelry, education, and pharmaceutical industries.

The NDRC appears to be becoming more aggressive in enforcing antitrust regulations. On August 21, Reuters reported on a closed-door meeting between several US multinational companies and an NDRC official. According to anonymous sources who allegedly attended the meeting, the NDRC official pressured foreign companies' in-house lawyers to confess to violations and warned them against retaining counsel to defend against government investigations. The NDRC has targeted 60 pharmaceutical companies, including several multinationals, as part of an ongoing probe into pricing and cost-calculation issues in the industry. In August, the NDRC imposed a total $110 million fine on six infant formula manufacturers, including five foreign manufacturers. This $110 million total represents the largest fine in the history of Chinese anti-monopoly enforcement.

On August 29, Kunming's local Ministry of Health announced a special project to require Kunming hospitals to review the purchasing, quality, use, and tracking of implantable medical devices. This follows an August 15 announcement by the local Beijing Ministry of Health to conduct a similar review, as well as statements by the local Ministries of Health in Xi’an and Shanghai announcing reviews of the use of implantable medical devices and quality management of physiotherapy medical devices, respectively.

Pharmaceuticals

New Media Reports

The The 21st Century Business Herald has published several articles on this topic, including the paper’s previously mentioned September 6 article on excessive medical care. This report also discussed the pharmaceutical sector, alleging that overprescription was caused in part by doctors supplementing their income with kickbacks from pharmaceutical companies. The article states that kickbacks on intravenous drip medications are higher than kickbacks on oral medications, leading to IV medication being a treatment of choice in Chinese hospitals. The article further alleges that if doctors prescribe medicines for a year or more, pharmaceutical companies will sponsor them on holidays or overseas trips. Finally, the article claims that kickbacks on formulated Chinese medicines are particularly common, at 20 to 30 percent, and that kickbacks on antibiotics are approximately 30 percent.

On September 10, The 21st Century Business Herald published allegations that a major local manufacturer of insulin has paid close to 800 million RMB of bribes from 2008 to the present. Prior anonymous allegations published by the The 21st Century Business Herald had focused on foreign pharmaceutical companies; this appears to be the first major media report of misconduct by a named local company.

Enforcement Actions

On August 29, Kunming, the capital of Yunnan Province, announced an investigation into bribery and misconduct in the city's health care system. This announcement was notable for two reasons. First, prior enforcement actions had generally been focused on larger, costal cities, whereas Kunming is a smaller, inland city. Additionally, the Kunming enforcement action involves the Public Security Bureau (PSB), or police. Prior investigations had mostly involved administrative, rather than criminal, enforcement agencies. 

Previously, the local Chengdu Ministry of Health and the Dalian Administration of Industry and Commerce (AIC) had announced administrative actions targeting bribery in the pharmaceutical and medical services sectors.

Questionable Vendors

During the course of media reporting on these matters, three travel agencies have been named as being potentially involved in misconduct: Linjiang Travel Agency, Kanghui Travel Agency (also known as China Comfort Travel Agency), and China Peace International Travel Agency.

Media reports have also alleged that local pharmaceutical distributors have been involved in misconduct. Given the current enforcement environment, companies may wish to pro-actively review their vendor relationships.


1  The official name of the agency.

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© Reed Smith | Attorney Advertising

Written by:

Reed Smith
Contact
more
less

Reed Smith on:

Readers' Choice 2017
Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
Sign up using*

Already signed up? Log in here

*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
Privacy Policy (Updated: October 8, 2015):
hide

JD Supra provides users with access to its legal industry publishing services (the "Service") through its website (the "Website") as well as through other sources. Our policies with regard to data collection and use of personal information of users of the Service, regardless of the manner in which users access the Service, and visitors to the Website are set forth in this statement ("Policy"). By using the Service, you signify your acceptance of this Policy.

Information Collection and Use by JD Supra

JD Supra collects users' names, companies, titles, e-mail address and industry. JD Supra also tracks the pages that users visit, logs IP addresses and aggregates non-personally identifiable user data and browser type. This data is gathered using cookies and other technologies.

The information and data collected is used to authenticate users and to send notifications relating to the Service, including email alerts to which users have subscribed; to manage the Service and Website, to improve the Service and to customize the user's experience. This information is also provided to the authors of the content to give them insight into their readership and help them to improve their content, so that it is most useful for our users.

JD Supra does not sell, rent or otherwise provide your details to third parties, other than to the authors of the content on JD Supra.

If you prefer not to enable cookies, you may change your browser settings to disable cookies; however, please note that rejecting cookies while visiting the Website may result in certain parts of the Website not operating correctly or as efficiently as if cookies were allowed.

Email Choice/Opt-out

Users who opt in to receive emails may choose to no longer receive e-mail updates and newsletters by selecting the "opt-out of future email" option in the email they receive from JD Supra or in their JD Supra account management screen.

Security

JD Supra takes reasonable precautions to insure that user information is kept private. We restrict access to user information to those individuals who reasonably need access to perform their job functions, such as our third party email service, customer service personnel and technical staff. However, please note that no method of transmitting or storing data is completely secure and we cannot guarantee the security of user information. Unauthorized entry or use, hardware or software failure, and other factors may compromise the security of user information at any time.

If you have reason to believe that your interaction with us is no longer secure, you must immediately notify us of the problem by contacting us at info@jdsupra.com. In the unlikely event that we believe that the security of your user information in our possession or control may have been compromised, we may seek to notify you of that development and, if so, will endeavor to do so as promptly as practicable under the circumstances.

Sharing and Disclosure of Information JD Supra Collects

Except as otherwise described in this privacy statement, JD Supra will not disclose personal information to any third party unless we believe that disclosure is necessary to: (1) comply with applicable laws; (2) respond to governmental inquiries or requests; (3) comply with valid legal process; (4) protect the rights, privacy, safety or property of JD Supra, users of the Service, Website visitors or the public; (5) permit us to pursue available remedies or limit the damages that we may sustain; and (6) enforce our Terms & Conditions of Use.

In the event there is a change in the corporate structure of JD Supra such as, but not limited to, merger, consolidation, sale, liquidation or transfer of substantial assets, JD Supra may, in its sole discretion, transfer, sell or assign information collected on and through the Service to one or more affiliated or unaffiliated third parties.

Links to Other Websites

This Website and the Service may contain links to other websites. The operator of such other websites may collect information about you, including through cookies or other technologies. If you are using the Service through the Website and link to another site, you will leave the Website and this Policy will not apply to your use of and activity on those other sites. We encourage you to read the legal notices posted on those sites, including their privacy policies. We shall have no responsibility or liability for your visitation to, and the data collection and use practices of, such other sites. This Policy applies solely to the information collected in connection with your use of this Website and does not apply to any practices conducted offline or in connection with any other websites.

Changes in Our Privacy Policy

We reserve the right to change this Policy at any time. Please refer to the date at the top of this page to determine when this Policy was last revised. Any changes to our privacy policy will become effective upon posting of the revised policy on the Website. By continuing to use the Service or Website following such changes, you will be deemed to have agreed to such changes. If you do not agree with the terms of this Policy, as it may be amended from time to time, in whole or part, please do not continue using the Service or the Website.

Contacting JD Supra

If you have any questions about this privacy statement, the practices of this site, your dealings with this Web site, or if you would like to change any of the information you have provided to us, please contact us at: info@jdsupra.com.

- hide
*With LinkedIn, you don't need to create a separate login to manage your free JD Supra account, and we can make suggestions based on your needs and interests. We will not post anything on LinkedIn in your name. Or, sign up using your email address.
Feedback? Tell us what you think of the new jdsupra.com!